Urinary tract infections (UTIs), especially common in women, are becoming harder to treat due to rising antibiotic resistance.
+
GlaxoSmithKline’s newly FDA-approved drug, Blujepa (gepotidacin), is the first oral antibiotic for UTIs in nearly 30 years. It targets two bacterial enzymes simultaneously, making it harder for bacteria to develop resistance.
+
Clinical trials show it was effective and well tolerated, with mild side effects.
—
h/t: Technology Networks
•••
pharmaceuticals